AVROBIO, Inc. (NASDAQ:AVRO – Get Free Report) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 1,770,000 shares, a decrease of 18.4% from the August 15th total of 2,170,000 shares. Currently, 4.6% of the shares of the stock are short sold. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 1.5 days.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. Wells Fargo & Company decreased their target price on AVROBIO from $2.50 to $2.00 in a research report on Thursday, July 13th. Wedbush downgraded AVROBIO from an “outperform” rating to a “neutral” rating in a research report on Wednesday, July 12th.
Institutional Trading of AVROBIO
AVROBIO Trading Down 0.3 %
Shares of AVRO stock traded down $0.01 on Monday, hitting $1.56. The company had a trading volume of 118,722 shares, compared to its average volume of 1,624,344. The stock’s 50-day moving average is $1.50 and its two-hundred day moving average is $1.18. AVROBIO has a twelve month low of $0.56 and a twelve month high of $1.93.
AVROBIO (NASDAQ:AVRO – Get Free Report) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.35 by ($1.72). On average, equities research analysts forecast that AVROBIO will post 0.65 earnings per share for the current year.
AVROBIO, Inc, a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.
- Five stocks we like better than AVROBIO
- What is the Dow Jones Industrial Average (DJIA)?
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Investors Need to Know to Beat the Market
- 5 Reasons Mullen Automotive is About to Turn a Corner
- What Is WallStreetBets and What Stocks Are They Targeting?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.